Addressing the challenge of platinum-resistant ovarian cancer: the role of mirvetuximab soravtansine

被引：0
|
作者：
Shaukat, Ayesha [1 ]
Shakeel, Laiba [1 ]
Khan, Afsheen [1 ]
Irfan, Hamza [2 ]
Akilimali, Aymar [3 ]
机构：
[1] Dow Univ Hlth Sci, Dept Internal Med, Karachi, Pakistan
[2] Shaikh Khalifa Bin Zayed Al Nahyan Med & Dent Coll, Dept Internal Med, Lahore, Pakistan
[3] Med Res Circle, Dept Res, Goma, DEM REP CONGO
来源：
ANNALS OF MEDICINE AND SURGERY | 2025年 / 87卷 / 01期
关键词：
EXPRESSION; CISPLATIN; WOMEN;
D O I：
10.1097/MS9.0000000000002759
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 7
页数：7
相关论文
共 50 条
  • [21] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
    Matulonis, Ursula A. A.
    Lorusso, Domenica
    Oaknin, Ana
    Pignata, Sandro
    Dean, Andrew
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A. A.
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth G. G.
    Wang, Jiuzhou
    Noble, Elizabeth
    Esteves, Brooke
    Method, Michael
    Coleman, Robert L. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) : 2436 - +
  • [22] Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
    Matulonis, Ursula
    Lorusso, Domenica
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason
    Romeo Marin, Margarita
    Harter, Philipp
    Murphy, Conleth
    Wang, Jiuzhou
    Noble, Elizabeth
    Esteves, Brooke
    Method, Michael
    Coleman, Robert
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S50 - S50
  • [23] Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (06) : 402 - 402
  • [24] Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
    Sassu, Carolina Maria
    Palaia, Innocenza
    Boccia, Serena Maria
    Caruso, Giuseppe
    Perniola, Giorgia
    Tomao, Federica
    Di Donato, Violante
    Musella, Angela
    Muzii, Ludovico
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [25] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
    Matulonis, Ursula A.
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason A.
    Romeo, Marga
    Harter, Philipp
    Murphy, Conleth G.
    Wang, Jiuzhou
    Method, Michael W.
    Esteves, Brooke
    Coleman, Robert L.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
    Gilbert, Lucy
    Oaknin, Ana
    Matulonis, Ursula A.
    Mantia-Smaldone, Gina M.
    Lim, Peter C.
    Castro, Cesar M.
    Provencher, Diane
    Memarzadeh, Sanaz
    Method, Michael
    Wang, Jiuzhou
    Moore, Kathleen N.
    O'Malley, David M.
    GYNECOLOGIC ONCOLOGY, 2023, 170 : 241 - 247
  • [27] Treosulfan in platinum-resistant ovarian cancer
    Olesen, Katrine Dam
    Larsen, Anja Tolstrup Raedkjaer
    Jensen, Lars Henrik
    Steffensen, Karina Dahl
    Sondergaard, Stine Rauff
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (07) : 1045 - 1051
  • [28] Immunotherapy for platinum-resistant ovarian cancer
    Bogani, Giorgio
    Lopez, Salvatore
    Mantiero, Mara
    Ducceschi, Monika
    Bosio, Sara
    Ruisi, Simona
    Sarpietro, Giuseppe
    Guerrisi, Rocco
    Brusadelli, Claudia
    Dell'Acqua, Andrea
    Di Donato, Violante
    Raspagliesi, Francesco
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 484 - 488
  • [29] Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
    O'Malley, David M.
    Matulonis, Ursula A.
    Birrer, Michael J.
    Castro, Cesar M.
    Gilbert, Lucy
    Vergote, Ignace
    Martin, Lainie P.
    Mantia-Smaldone, Gina M.
    Gonzalez Martin, Antonio
    Bratos, Raquel
    Penson, Richard T.
    Malek, Karim
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 379 - 385
  • [30] Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
    Coleman, Robert L.
    Lorusso, Domenica
    Oaknin, Ana
    Cecere, Sabrina Chiara
    Denys, Hannelore
    Colombo, Nicoletta
    van Gorp, Toon
    Konner, Jason A.
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth
    Wang, Yuemei
    Esteves, Brooke
    Method, Michael
    Matulonis, Ursula
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (08) : 1119 - 1125
12345